Geovax Labs Inc Financials

GOVXW

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Geovax Labs Inc (GOVXW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 24 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI GOVXW FY2025 2026-04-22

GeoVax Labs functions as a capital-funded R&D platform, where equity financing rather than product sales keeps operations moving.

Recent results show operating cash burn easing from $24.7M to $21.5M, but it still dwarfed revenue, showing costs are set mainly by research activity rather than sales volume. That matters because year-end cash was only $3.1M after $19.1M of financing inflow, so the balance sheet functioned as a funding bridge instead of a self-financing operation.

The spending mix is distinctly development-stage: R&D was $18.1M versus $6.0M of SG&A. With capex only $28K, cash use is going into programs and personnel rather than factories or equipment, which is why free cash flow stays close to operating cash flow.

This is not a debt-driven story: total liabilities were just $2.5M against cash of $3.1M, and no long-term debt is reported. But liquidity optics can be misleading here; a 2.7x current ratio does not offset cash needs created by ongoing research spending rather than inventory or receivable build.

Financial Health Signals

Financial Health Score 32/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Geovax Labs Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Geovax Labs Inc has an operating margin of -869.3%, meaning the company retains $-869 of operating profit per $100 of revenue. This below-average margin results in a low score of 26/100, suggesting thin profitability after operating expenses. This is down from -635.8% the prior year.

Growth

Geovax Labs Inc's revenue declined 37.1% year-over-year, from $4.0M to $2.5M. This contraction results in a growth score of 2/100.

Leverage

Geovax Labs Inc has a moderate D/E ratio of 0.66. This balance of debt and equity financing earns a leverage score of 55/100.

Liquidity

With a current ratio of 2.74, Geovax Labs Inc holds $2.74 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 73/100.

Cash Flow

While Geovax Labs Inc generated -$21.5M in operating cash flow, capex of $28K consumed most of it, leaving -$21.5M in free cash flow. This results in a low score of 2/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Geovax Labs Inc's ROE of -561.2% shows moderate profitability relative to equity, earning a score of 31/100. This is down from -495.0% the prior year.

Piotroski F-Score Partial

1/7

Geovax Labs Inc passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). No profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Low Quality

1.00x

For every $1 of reported earnings, Geovax Labs Inc generates $1.00 in operating cash flow (-$21.5M OCF vs -$21.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$2.5M

YoY-37.1%

5Y CAGR+6.4%

Geovax Labs Inc generated $2.5M in revenue in fiscal year 2025. This represents a decrease of 37.1% from the prior year.

EBITDA

-$21.6M

YoY+13.9%

Geovax Labs Inc's EBITDA was -$21.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 13.9% from the prior year.

Net Income

-$21.5M

YoY+14.1%

Geovax Labs Inc reported -$21.5M in net income in fiscal year 2025. This represents an increase of 14.1% from the prior year.

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

-$21.5M

YoY+12.9%

Geovax Labs Inc generated -$21.5M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 12.9% from the prior year.

Cash & Debt

$3.1M

YoY-44.0%

5Y CAGR-20.8%

10Y CAGR+11.3%

Geovax Labs Inc held $3.1M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

Geovax Labs Inc had 2M shares outstanding in fiscal year 2025.

Margins & Returns

Gross Margin

N/A

Operating Margin

-869.3%

YoY-233.5pp

5Y CAGR-714.9pp

Geovax Labs Inc's operating margin was -869.3% in fiscal year 2025, reflecting core business profitability. This is down 233.5 percentage points from the prior year.

Net Margin

-862.3%

YoY-230.4pp

5Y CAGR-700.1pp

Geovax Labs Inc's net profit margin was -862.3% in fiscal year 2025, showing the share of revenue converted to profit. This is down 230.4 percentage points from the prior year.

Return on Equity

-561.2%

YoY-66.1pp

5Y CAGR-530.2pp

10Y CAGR-337.9pp

Geovax Labs Inc's ROE was -561.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 66.1 percentage points from the prior year.

Capital Allocation

R&D Spending

$18.1M

YoY-23.6%

5Y CAGR+49.3%

10Y CAGR+26.8%

Geovax Labs Inc invested $18.1M in research and development in fiscal year 2025. This represents a decrease of 23.6% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$28K

YoY+33.7%

5Y CAGR-29.3%

10Y CAGR+5.7%

Geovax Labs Inc invested $28K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 33.7% from the prior year.

GOVXW Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$2.5M-37.1%	$4.0M	$0-100.0%	$82K-78.9%	$386K-78.9%	$1.8M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$18.1M-23.6%	$23.7M+14.4%	$20.7M+127.1%	$9.1M-41.3%	$15.6M+536.3%	$2.4M
SG&A Expenses	$6.0M+11.5%	$5.4M-10.6%	$6.0M+20.8%	$5.0M+39.4%	$3.6M+62.9%	$2.2M
Operating Income	-$21.6M+13.9%	-$25.1M+6.0%	-$26.7M-90.6%	-$14.0M+25.2%	-$18.7M-565.5%	-$2.8M
Interest Expense	$0-100.0%	$21K	$0	$0-100.0%	$1K-99.1%	$144K
Income Tax	$0	N/A	N/A	N/A	$0	$0
Net Income	-$21.5M+14.1%	-$25.0M+3.8%	-$26.0M-85.2%	-$14.0M+24.5%	-$18.6M-527.8%	-$3.0M
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$0	N/A	$0-100.0%	$852K-47.9%	$1.6M	N/A	$2.8M+827.7%	$301K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$3.9M	N/A	$5.0M+6.7%	$4.7M-11.7%	$5.4M	N/A	$7.4M+73.1%	$4.3M
SG&A Expenses	$1.4M	N/A	$1.3M-13.8%	$1.5M-8.6%	$1.7M	N/A	$1.2M+14.3%	$1.1M
Operating Income	-$5.3M	N/A	-$6.4M-17.6%	-$5.4M-0.3%	-$5.4M	N/A	-$5.9M-15.7%	-$5.1M
Interest Expense	N/A	N/A	$0	$0	N/A	N/A	$14K+93.1%	$7K
Income Tax	$0	N/A	N/A	N/A	$0	N/A	N/A	N/A
Net Income	-$5.3M	N/A	-$6.3M-17.7%	-$5.4M-0.2%	-$5.4M	N/A	-$5.8M-14.8%	-$5.1M
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

GOVXW Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$6.3M-22.2%	$8.2M-12.1%	$9.3M-70.4%	$31.3M+165.7%	$11.8M+13.5%	$10.4M
Current Assets	$5.3M-33.0%	$7.9M+0.6%	$7.9M-72.8%	$28.9M+148.8%	$11.6M+13.6%	$10.2M
Cash & Equivalents	$3.1M-44.0%	$5.5M-14.7%	$6.5M-76.6%	$27.6M+141.7%	$11.4M+15.6%	$9.9M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$0-100.0%	$659K	$0	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.5M-19.0%	$3.1M-11.7%	$3.5M-25.9%	$4.7M-36.1%	$7.4M+801.2%	$825K
Current Liabilities	$1.9M-37.7%	$3.1M-11.7%	$3.5M-25.9%	$4.7M-12.6%	$5.4M+570.8%	$810K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$3.8M-24.2%	$5.0M-12.4%	$5.8M-78.3%	$26.6M+509.9%	$4.4M-54.4%	$9.6M
Retained Earnings	-$150.8M-16.6%	-$129.4M-23.9%	-$104.4M-33.1%	-$78.4M-21.8%	-$64.4M-40.5%	-$45.8M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$3.0M-53.0%	$6.3M-5.8%	$6.7M+25.8%	$5.4M-50.6%	$10.8M+32.8%	$8.2M-26.6%	$11.1M+171.4%	$4.1M
Current Assets	$2.4M-54.3%	$5.3M-18.5%	$6.5M+26.9%	$5.1M-51.6%	$10.6M+33.7%	$7.9M-27.0%	$10.9M+182.8%	$3.8M
Cash & Equivalents	$1.3M-58.8%	$3.1M-38.4%	$5.0M+61.9%	$3.1M-58.4%	$7.4M+35.1%	$5.5M-35.9%	$8.6M+450.2%	$1.6M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	$0	$0-100.0%	$533K-64.4%	$1.5M+127.1%	$659K+20.4%	$548K+82.1%	$301K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.5M-1.1%	$2.5M+38.0%	$1.8M-27.9%	$2.5M-13.8%	$2.9M-5.5%	$3.1M+19.1%	$2.6M-59.3%	$6.4M
Current Liabilities	$2.3M+18.3%	$1.9M+6.2%	$1.8M-27.9%	$2.5M-13.8%	$2.9M-5.5%	$3.1M+19.1%	$2.6M-59.3%	$6.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$494K-87.1%	$3.8M-22.0%	$4.9M+73.9%	$2.8M-64.3%	$7.9M+56.4%	$5.0M-40.6%	$8.5M+468.3%	-$2.3M
Retained Earnings	-$156.1M-3.5%	-$150.8M-3.0%	-$146.4M-4.5%	-$140.1M-4.0%	-$134.7M-4.1%	-$129.4M-6.8%	-$121.1M-5.0%	-$115.3M

GOVXW Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$21.5M+13.0%	-$24.7M+2.0%	-$25.2M-32.3%	-$19.0M-70.0%	-$11.2M-307.1%	-$2.8M
Capital Expenditures	$28K+33.7%	$21K-57.8%	$49K-63.5%	$134K+181.4%	$48K-69.6%	$157K
Free Cash Flow	-$21.5M+12.9%	-$24.7M+2.1%	-$25.2M-31.6%	-$19.2M-70.4%	-$11.2M-286.7%	-$2.9M
Investing Cash Flow	-$28K-33.7%	-$21K+57.8%	-$49K+63.5%	-$134K-181.4%	-$48K+69.6%	-$157K
Financing Cash Flow	$19.1M-19.7%	$23.8M+484.6%	$4.1M-88.5%	$35.4M+176.5%	$12.8M+2.2%	$12.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$3.5M+28.7%	-$5.0M+20.1%	-$6.2M-43.3%	-$4.3M+27.3%	-$6.0M+23.1%	-$7.8M+16.6%	-$9.3M-379.0%	-$1.9M
Capital Expenditures	$0	$0	$0-100.0%	$11K-36.6%	$17K	$0-100.0%	$21K	$0
Free Cash Flow	-$3.5M+28.7%	-$5.0M+20.1%	-$6.2M-43.0%	-$4.3M+27.4%	-$6.0M+22.8%	-$7.8M+16.8%	-$9.3M-380.0%	-$1.9M
Investing Cash Flow	$0	$0	$0+100.0%	-$11K+36.6%	-$17K	$0+100.0%	-$21K	$0
Financing Cash Flow	$1.7M-43.3%	$3.0M-62.6%	$8.1M+3888536.4%	$209-100.0%	$7.9M+69.5%	$4.7M-71.4%	$16.3M+498.0%	$2.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

GOVXW Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-869.3%-233.5pp	-635.8%	N/A	-17207.5%-12344.8pp	-4862.7%-4708.3pp	-154.5%
Net Margin	-862.3%-230.4pp	-632.0%	N/A	-17198.3%-12381.2pp	-4817.2%-4655.0pp	-162.2%
Return on Equity	-561.2%-66.1pp	-495.0%-44.5pp	-450.5%-397.8pp	-52.7%+373.1pp	-425.8%-394.9pp	-30.9%
Return on Assets	-338.5%-32.0pp	-306.4%-26.7pp	-279.7%-235.0pp	-44.7%+112.7pp	-157.4%-129.0pp	-28.5%
Current Ratio	2.74+0.2	2.55+0.3	2.24-3.9	6.10+4.0	2.14-10.5	12.63
Debt-to-Equity	0.66+0.0	0.620.0	0.61+0.4	0.18-1.5	1.70+1.6	0.09
FCF Margin	-863.8%-239.3pp	-624.5%	N/A	-23507.2%-20590.4pp	-2916.8%-2757.3pp	-159.4%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	-635.8%-305.6pp	-330.2%	N/A	-209.9%+1473.7pp	-1683.6%
Net Margin	N/A	N/A	N/A	-630.1%-302.7pp	-327.3%	N/A	-208.5%+1475.7pp	-1684.2%
Return on Equity	-1065.7%	N/A	-128.8%+61.6pp	-190.3%-122.5pp	-67.8%	N/A	-68.4%	N/A
Return on Assets	-176.4%	N/A	-93.9%+6.5pp	-100.4%-50.9pp	-49.5%	N/A	-52.3%+71.3pp	-123.7%
Current Ratio	1.06-1.7	2.74-0.8	3.57+1.5	2.03-1.6	3.62+1.1	2.55-1.6	4.17+3.6	0.60
Debt-to-Equity	5.04+4.4	0.66+0.3	0.37-0.5	0.90+0.5	0.37-0.2	0.62+0.3	0.31+3.1	-2.77
FCF Margin	N/A	N/A	N/A	-509.8%-144.3pp	-365.5%	N/A	-334.0%+311.5pp	-645.6%

Similar Companies

Estrella Immunopharma ESLAW

Briacell Therapeutics Corp BCTXW

Celularity Inc CELUW

Pasithea Therapeutics Corp KTTAW

NKGen Biotech NKGNW

Frequently Asked Questions

What is Geovax Labs Inc's annual revenue?

Geovax Labs Inc (GOVXW) reported $2.5M in total revenue for fiscal year 2025. This represents a -37.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Geovax Labs Inc's revenue growing?

Geovax Labs Inc (GOVXW) revenue declined by 37.1% year-over-year, from $4.0M to $2.5M in fiscal year 2025.

Is Geovax Labs Inc profitable?

No, Geovax Labs Inc (GOVXW) reported a net income of -$21.5M in fiscal year 2025, with a net profit margin of -862.3%.

What is Geovax Labs Inc's EBITDA?

Geovax Labs Inc (GOVXW) had EBITDA of -$21.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Geovax Labs Inc's operating margin?

Geovax Labs Inc (GOVXW) had an operating margin of -869.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Geovax Labs Inc's net profit margin?

Geovax Labs Inc (GOVXW) had a net profit margin of -862.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Geovax Labs Inc's return on equity (ROE)?

Geovax Labs Inc (GOVXW) has a return on equity of -561.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Geovax Labs Inc's free cash flow?

Geovax Labs Inc (GOVXW) generated -$21.5M in free cash flow during fiscal year 2025. This represents a 12.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Geovax Labs Inc's operating cash flow?

Geovax Labs Inc (GOVXW) generated -$21.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Geovax Labs Inc's total assets?

Geovax Labs Inc (GOVXW) had $6.3M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Geovax Labs Inc's capital expenditures?

Geovax Labs Inc (GOVXW) invested $28K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Geovax Labs Inc spend on research and development?

Geovax Labs Inc (GOVXW) invested $18.1M in research and development during fiscal year 2025.

How many shares does Geovax Labs Inc have outstanding?

Geovax Labs Inc (GOVXW) had 2M shares outstanding as of fiscal year 2025.

What is Geovax Labs Inc's current ratio?

Geovax Labs Inc (GOVXW) had a current ratio of 2.74 as of fiscal year 2025, which is generally considered healthy.

What is Geovax Labs Inc's debt-to-equity ratio?

Geovax Labs Inc (GOVXW) had a debt-to-equity ratio of 0.66 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Geovax Labs Inc's return on assets (ROA)?

Geovax Labs Inc (GOVXW) had a return on assets of -338.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Geovax Labs Inc's cash runway?

Based on fiscal year 2025 data, Geovax Labs Inc (GOVXW) had $3.1M in cash against an annual operating cash burn of $21.5M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Geovax Labs Inc's Piotroski F-Score?

Geovax Labs Inc (GOVXW) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Geovax Labs Inc's earnings high quality?

Geovax Labs Inc (GOVXW) has an earnings quality ratio of 1.00x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Geovax Labs Inc?

Geovax Labs Inc (GOVXW) scores 32 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.